A rare case of Epstein–Barr virus‐related plasmacytoma involving maxillary sinus mucosa

Gibbs, Julie; Leon, Marino E.; Liu, Kenia; Nguyen, Jenny; Zhang, Ling

doi:10.1002/ccr3.959

Cited by 8 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Survival is variable ranging from 4 to 12 months. 9 Our case is a rare condition in an unusual site in an immunocompetent patient. His diagnosis was a challenge for primary and specialist clinicians and pathologists.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Unilateral Maxillary Sinus Plasmablastic Lymphoma in an Immunocompetent Patient. An Unusual Occurrence Report and Literature Review

2020

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a rare and aggressive form of mature B cell neoplasms almost exclusively identified in patients infected with the human immunodeficiency virus (HIV). The small number of HIV-negative PBL cases reported in the literature to date is composed of single case reports and small case series which characteristically are present involving the oral cavity mucosa or gingiva. We present a 72-year-old HIV-negative Australian patient without any cause of immunodeficiency, with an isolated left maxillary sinus PBL.

show abstract

Section: Discussionmentioning

confidence: 74%

“…>6 months Colomo et al 7 86-year-old Spanish male (À) ve (þ) ve Not described <4 months Saraceni et al 8 24-year-old American male (À) ve (þ) ve Hyper-CVAD þ RT 45 Gy. >4 years Gibbs et al 9 76-year-old American male (À) ve (þ) ve RT 180 À 450 Gy. >2 years Present study 2020 72-year-old Australian male (À) ve (þ) ve EPOCH >4 months…”

Section: Resultsmentioning

confidence: 99%

Unilateral Maxillary Sinus Plasmablastic Lymphoma in an Immunocompetent Patient. An Unusual Occurrence Report and Literature Review

2020

View full text Add to dashboard Cite

show abstract

“…Males are two to three times more likely to be affected 1861 . EMPs have been reported in association with EBV and HIV infection, although a causal relationship has not been definitively established 1864,1865 …”

Section: Sinonasal Lymphomamentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BackgroundSinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represents a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.MethodsIn accordance with prior ICAR documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.ResultsThe ICNST document consists of 4 major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.ConclusionAs an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.This article is protected by copyright. All rights reserved

show abstract

“…Moreover, EBV-positive PCN was mainly reported in immunodeficient patients, while only a few cases occurred in immunocompetent individuals. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] This leaves open the question whether the prevalence of EBV in PCN varies according to the histologic subtype and tumor location in immunocompetent patients. There is also limited information on the distinctive clinicopathological features of EBV-positive PCN, as well as the prognosis of patients with this rare entity.…”

mentioning

confidence: 99%

Epstein-Barr Virus–Positive Plasma Cell Neoplasms in Immunocompetent Patients

Xiao,

Lin,

et al. 2023

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV)-positive plasma cell neoplasms (PCNs) in immunocompetent patients are a rare entity, the clinicopathological and prognostic features of which have not been well characterized. Fifteen cases of EBV-positive PCN arising in immunocompetent patients from south China were retrospectively analyzed, and an additional 44 cases from the literature were reviewed. The overall EBV-positive rate defined by EBV-encoded small RNAs (EBERs) in-situ hybridization of PCNs was 12.3% (15/122), and it was significantly higher in plasmacytoma (17.1%, 13/76) than in plasma cell myeloma/multiple myeloma (4.3%, 2/46; P=0.031). The age of the patients ranged from 17 to 79 years, with a median age of 56 years. There was a large preponderance of men, with a male-to-female ratio of 4:1. Solitary plasmacytoma of bone (23.8%, 5/21) had comparable EBV-encoded small RNAs-positive rates with extramedullary plasmacytoma arising in the upper respiratory tract (19.5%, 8/41; P=0.949). Anaplastic and classic cytologic appearance was observed in 61.5% (8/13) and 38.5% (5/13) of EBV-positive plasmacytomas, respectively. Cases with an anaplastic cytologic appearance had a significantly higher Ki-67 proliferation index than those with a classic cytologic appearance (median: 55% vs. 10%, P=0.001). In the combined cohorts, anaplastic/plasmablastic cytologic appearance was significantly more common in extramedullary plasmacytoma arising in the upper respiratory tract (72.0%, 18/25) than outside the upper respiratory tract (11.1%, 1/9; P=0.006). Among the 59 cases of EBV-positive PCN, survival data of 34 cases were available for analysis, including 30 cases of plasmacytoma and 4 cases of plasma cell myeloma/multiple myeloma. There was no statistically significant difference in overall survival between patients with EBV-positive plasmacytomas in the combined cohorts and EBV-negative plasmacytomas in the present cohort. The prevalence of EBV in PCN in immunocompetent patients varies according to histologic subtype and tumor location. Compared with EBV-negative cases, EBV-positive plasmacytomas tend to have an anaplastic/plasmablastic cytologic appearance. No significant impact of EBV infection on clinical outcomes is observed in the limited number of reported cases.

show abstract

A rare case of Epstein–Barr virus‐related plasmacytoma involving maxillary sinus mucosa

Cited by 8 publications

References 6 publications

Unilateral Maxillary Sinus Plasmablastic Lymphoma in an Immunocompetent Patient. An Unusual Occurrence Report and Literature Review

Unilateral Maxillary Sinus Plasmablastic Lymphoma in an Immunocompetent Patient. An Unusual Occurrence Report and Literature Review

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Epstein-Barr Virus–Positive Plasma Cell Neoplasms in Immunocompetent Patients

Contact Info

Product

Resources

About